Bayer's finerenone approved in India for heart failure

The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more

Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets

Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women

FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency

Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.

Akums Drugs gets 20- year patent for "Dual Release Gastro-Resistant Composition"

The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease

Lilly to build $3 billion oral medicine facility in Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain

Kimberly-Clark to acquire Kenvue in $48.7 billion mega deal

Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms